Florida Cancer Specialists & Research Institute, LLC (FCS) is pleased to announce that Board-certified hematologist and medical oncologist Jayan Nair, MD has joined the the Sarasota Downtown clinical team.
Florida Cancer Specialists & Research Institute, LLC (FCS) is pleased to announce the promotion of a member of its executive leadership team, Paul Chadwick, to Chief Value and Procurement Officer. Paul will continue reporting to Chief Executive Officer Nathan H. Walcker. The statewide practice also welcomed Frank Scimeca, PharmD, MBA, BCOP as vice president, pharmacy services, reporting to Paul Chadwick, effective July 17, 2023.
FCS physicians and senior leaders are co-authors of a study that confirms the effectiveness of trilaciclib for the treatment of adult patients with Extensive-Stage Small Cell Lung Cancer. Trilaciclib is the first FDA-approved therapy in its class to help protect bone marrow cells from damage caused by chemotherapy.
Lucio Gordan, MD, President & Managing Physician of Florida Cancer Specialists & Research Institute, LLC (FCS), talked with Kevin Keegan, General Manager of Oncology Business with Illumina, about how FCS is bringing precision oncology through analysis of real-world data, innovative technology and research to cancer patients being treated in community settings.
Smoothies can be a great way to get fruit and vegetables into your diet, and even grains (more about that later). But are they as good as actually eating those fruits and vegetables?
FCS Top News Updates
FCS Real-World Evidence Abstract Highlights Progress and Gaps in Biomarker Testing for Lung Cancer
FCS Study Finds Comparable Quality and Safety Outcomes in CAR T-Cell Therapy Across Accredited and Non-Accredited Centers, Highlighting Care Location as Key Driver of Patient Access and Experience